RxDoctor Payments Data

Mary Elliott, PA

Physician Assistant · Guilford, CTNPI 1710594403

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 83.6% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $38,043, more than ten times the $269 reported in 2022. Among physician assistant clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$42,668in general payments, 2019–2025

Across 312 payments — averaging $136.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$36K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Amgen$969
  • E.r. Squibb & Sons, L.L.C.$504
  • AstraZeneca$317
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$1,3603%
  • Speaking & faculty fees$22,86554%
  • Travel & lodging$10,21724%
  • Food & beverage$8,02819%
  • Education$1980%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,668 in reported general payments places this provider in the 95th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$137,465
Medicare patients
122
Services billed
4,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$179,802
OtezlaApremilast17$86,794
Prednisone304$2,315
Hydroxychloroquine Sulfate78$2,194
Febuxostat18$2,006
MethotrexateMethotrexate Sodium117$1,908
Celecoxib13$1,209
Duloxetine Hcl18$562
Gabapentin32$379
Allopurinol51$268
Folic Acid29$250
Tramadol Hcl26$214
Meloxicam62$141
Methylprednisolone12$97
Amlodipine Besylate12$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$969$86,79417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Guilford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →